Withings BeamO securely captures heart and lung data at home – and shares it securely with your doctor for more effective ...
STK-012 is an α/β biased IL-2 partial agonist designed to stimulate antigen-activated T cells while avoiding IL-2 associated toxicities Positive Phase 1b data recently presented at SITC 2025, with a ...
Synthekine Inc., an engineered cytokine therapeutics company, today announced that the company has dosed the first patient in the SYNERGY-101 study. SYNERGY-101 is a global, randomized Phase 2 ...
Maintaining optimal lung health is essential for overall well-being, especially in today’s world, where respiratory conditions and environmental toxins are prevalent. While the lungs have a natural ...
MannKind Corporation (MNKD) saw a stock decline after the announcement that it would discontinue its trial testing MNKD-101, a nebulized form of clofazimine intended for treating refractory ...
MannKind Corporation (NASDAQ:MNKD) announced Monday that it has discontinued its Phase 3 clinical trial evaluating MNKD-101, a nebulized inhalation suspension of clofazimine, for the treatment of ...
Mirah first made waves way back in 2000 with her debut You Think It's Like This But Really It's Like This, an album that established the then-Olympia-based artist as a fixture of the mid-'90s Pacific ...
Estimated median progression free survival (PFS) in third-line treatment (180 mg dose) was 5.6 months. The comparable PFS threshold in standard of care treatments is 2.5 months1. Estimated median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results